EC95 of Remifentanil for Preventing Cough

Ajou University School of Medicine

Status: Completed

Conditions: Drug Usage

Treatments: Drug: Remifentanil; Drug: Propofol anesthesia

Study type: Interventional

Funder types: Other

Identifiers

NCT02973724

AJIRB-MED-CT4-16-349

Details and patient eligibility

About

The investigator designed this study to investigate remifentanil effect-site concentration in 95% of patients (EC95) for preventing cough after laryngomicrosurgery from propofol anesthesia.

Full description

At the end of the surgery, propofol infusion was stopped and remifentanil was titrated to predetermined (initial concentration 1.0 ng/ml for the first patient). Extubation was performed when the patients opened their eyes and spontaneous respiration and adequate tidal volume and ventilatory frequency were confirmed.

Enrollment: 40 patients

Sex: All

Ages: 19 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ASA I-II patients undergoing general anesthesia for laryngomicrosurgery

Exclusion criteria

• Anticipated difficult airway
• COPD, Asthma
• Recent URI (< 2 weeks)
• Severe cardiac, hepatic renal disease

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

40 participants in 1 patient group

Remifentanil

Experimental group

Description:

Extubation was performed when remifentanil was maintained a predetermined concentration throughout the emergence periods.

Treatment:

Drug: Propofol anesthesia

Drug: Remifentanil